When building your watch list, look for stocks with an 80 or higher RS Rating. Fulgent Genetics now meets that criteria, with a jump from 78 to 86 Tuesday.
Hone Your Stock-Picking Skills By Focusing On These Factors
This exclusive rating from Investor's Business Daily identifies market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the last 52 weeks stacks up against all the other stocks in our database.
History shows that the stocks that go on to make the biggest gains often have an RS Rating of above 80 in the early stages of their moves.
Fulgent Genetics is trying to complete a consolidation with a 25.11 entry. See if it can clear the breakout price in heavy volume.
Fulgent Genetics saw both earnings and sales growth rise last quarter. Earnings-per-share increased from -86% to 0%. Revenue rose from 8% to 14%.
Fulgent Genetics earns the No. 1 rank among its peers in the Medical-Research Equipment/Services industry group. Tempus AI and Schrodinger are also among the group's highest-rated stocks.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
